Sign In
Buy ALIM
$5.54
+0 (+0%)
At Close: Dec 12, 2024
ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals
09:21am, Monday, 24'th Jun 2024
MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) to ANI P
Alimera Sciences stock rallies 75% on ANI Pharmaceuticals deal
08:08am, Monday, 24'th Jun 2024
Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million
ALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to Shareholders
07:54am, Monday, 24'th Jun 2024
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alimera Sciences, Inc. (NASDAQ: ALIM) to ANI Pharmaceuticals, Inc. for $5.50 per share in
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Tuesday, 04'th Jun 2024
ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, ph
Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Call Transcript
01:40pm, Tuesday, 14'th May 2024
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q1 2024 Earnings Conference Call May 14, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President and Chief Executive
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
09:41am, Tuesday, 14'th May 2024
Alimera Sciences (ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.71 per share a year ago.
Alimera Sciences Reports First Quarter 2024 Results
07:30am, Tuesday, 14'th May 2024
ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
08:00am, Tuesday, 19'th Mar 2024
Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy Protocol AL is studying ILUVIEN or faricimab (
New Strong Sell Stocks for March 13th
09:01am, Wednesday, 13'th Mar 2024
ASLE, ALIM and CADE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2024.
Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript
12:39pm, Thursday, 07'th Mar 2024
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q4 2023 Earnings Conference Call March 7, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President & Chief Executive
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
10:01am, Thursday, 07'th Mar 2024
Alimera Sciences (ALIM) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.54 per share a year ago.
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
07:30am, Thursday, 07'th Mar 2024
Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance
NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macu
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Tuesday, 02'nd Jan 2024
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, ph
ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, ph
